NewAmsterdam Pharma (NAMS) News Today $16.42 +1.30 (+8.60%) As of 04/14/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Arrowstreet Capital Limited Partnership Acquires New Shares in NewAmsterdam Pharma (NASDAQ:NAMS)Arrowstreet Capital Limited Partnership bought a new position in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 30,504 shares of the company's stock, valued at approximateApril 14 at 3:37 AM | marketbeat.comNewAmsterdam Pharma (NAMS): Among Billionaire Stanley Druckenmiller’s Top Stock Picks with Huge Upside PotentialApril 11, 2025 | msn.comCenterBook Partners LP Purchases 122,894 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)CenterBook Partners LP increased its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 143.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 208,589 shares of the company's stock after acquiriApril 11, 2025 | marketbeat.comNewAmsterdam Pharma's (NAMS) Buy Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and set a $42.00 target price on shares of NewAmsterdam Pharma in a research report on Tuesday.April 10, 2025 | marketbeat.comBrokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) PT at $43.33April 10, 2025 | americanbankingnews.comNewAmsterdam Pharma Company (NAMS) Receives a Buy from TD CowenApril 9, 2025 | markets.businessinsider.comNewAmsterdam Pharma (NASDAQ:NAMS) Sets New 52-Week Low - Here's WhyNewAmsterdam Pharma (NASDAQ:NAMS) Reaches New 1-Year Low - What's Next?April 9, 2025 | marketbeat.comNewAmsterdam Pharma Company (NAMS) Gets a Buy from NeedhamApril 9, 2025 | markets.businessinsider.com4NAMS : The Analyst Verdict: NewAmsterdam Pharma Co In The Eyes Of 6 ExpertsApril 8, 2025 | benzinga.comOvata Capital Management Ltd Takes Position in NewAmsterdam Pharma (NASDAQ:NAMS)Ovata Capital Management Ltd purchased a new position in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 150,000 shares of the company's stock, valued at aApril 7, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Receives Consensus Recommendation of "Buy" from AnalystsNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) has received an average rating of "Buy" from the six analysts that are covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages that have issued aApril 7, 2025 | marketbeat.comAlliancebernstein L.P. Acquires New Stake in NewAmsterdam Pharma (NASDAQ:NAMS)Alliancebernstein L.P. bought a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 1,858,065 shares of the company's stock, valued at approximately $47,7April 7, 2025 | marketbeat.comWellington Management Group LLP Acquires 2,222,900 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)Wellington Management Group LLP raised its holdings in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 2,410.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,315,123 shares of the company's stock after acquiring an additionaApril 7, 2025 | marketbeat.comPamalican Asset Management Ltd Makes New Investment in NewAmsterdam Pharma (NASDAQ:NAMS)Pamalican Asset Management Ltd purchased a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 30,000 shares of the company's stoApril 6, 2025 | marketbeat.comCinctive Capital Management LP Sells 57,055 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)Cinctive Capital Management LP trimmed its position in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 85.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 9,516 shares of the company's stock after selling 57,055 shares during the qApril 6, 2025 | marketbeat.comNewAmsterdam Pharma Co NV (NAMS) Announces Inducement Share Options for New HiresApril 4, 2025 | gurufocus.comNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 4, 2025 | globenewswire.comAmerican Century Companies Inc. Acquires Shares of 346,572 NewAmsterdam Pharma (NASDAQ:NAMS)American Century Companies Inc. acquired a new stake in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 346,572 shares of the coApril 4, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Sees Unusually-High Trading Volume - Here's WhyNewAmsterdam Pharma (NASDAQ:NAMS) Sees Large Volume Increase - Here's WhyApril 3, 2025 | marketbeat.comNewAmsterdam Pharma is Now Oversold (NAMS)April 3, 2025 | nasdaq.comNAMS Crosses Below Key Moving Average LevelApril 2, 2025 | nasdaq.comPiper Sandler Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)April 2, 2025 | markets.businessinsider.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Down 8.5% - Time to Sell?NewAmsterdam Pharma (NASDAQ:NAMS) Shares Down 8.5% - Here's What HappenedApril 1, 2025 | marketbeat.comWilliam Blair Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)April 1, 2025 | markets.businessinsider.comPictet Asset Management Holding SA Buys 140,605 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)Pictet Asset Management Holding SA increased its stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 13.8% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 1,157,452 shares of the company's stock after purchasing an addApril 1, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Sees Large Growth in Short InterestNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) saw a large growth in short interest in March. As of March 15th, there was short interest totalling 4,340,000 shares, a growth of 42.8% from the February 28th total of 3,040,000 shares. Currently, 7.5% of the shares of the stock are sold short. Based on an average daily volume of 843,800 shares, the short-interest ratio is presently 5.1 days.March 31, 2025 | marketbeat.comNewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare ConferenceMarch 31, 2025 | gurufocus.comNewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare ConferenceMarch 31, 2025 | globenewswire.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Acquired by Swiss National BankSwiss National Bank lifted its holdings in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 105.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 72,000 shares of the company's stock after buying an additional 36,900 shares during the perioMarch 30, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Director Buys $25,526.15 in StockNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) Director James N. Topper acquired 1,135 shares of the firm's stock in a transaction that occurred on Wednesday, March 26th. The shares were bought at an average price of $22.49 per share, for a total transaction of $25,526.15. Following the completion of the purchase, the director now owns 3,013,569 shares in the company, valued at $67,775,166.81. This trade represents a 0.04 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.March 29, 2025 | marketbeat.comJames N. Topper Buys 1,135 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) StockMarch 29, 2025 | insidertrades.comDirector Makes Bold Move with NewAmsterdam Pharma Stock Purchase!March 28, 2025 | tipranks.comDCF Advisers LLC Grows Position in NewAmsterdam Pharma (NASDAQ:NAMS)DCF Advisers LLC increased its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 162.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 89,400 shares of the company's stock after buying an additional 55,400 shares during thMarch 22, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Trading 3.4% Higher - What's Next?NewAmsterdam Pharma (NASDAQ:NAMS) Trading Up 3.4% - Here's WhyMarch 21, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Sold by US Bancorp DEUS Bancorp DE cut its holdings in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 80.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,804 shares of the company's stock after selling 11,619 shares during the period. US Bancorp DE's holdingsMarch 18, 2025 | marketbeat.comNewAmsterdam Pharma Company (NAMS) Gets a Buy from Piper SandlerMarch 12, 2025 | markets.businessinsider.comNewAmsterdam Pharma (NASDAQ:NAMS) Receives Consensus Rating of "Buy" from BrokeragesNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) has been assigned a consensus recommendation of "Buy" from the six ratings firms that are currently covering the stock, Marketbeat.com reports. Six research analysts have rated the stock with a buy rating. The average 1 year price target among anMarch 11, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Director James N. Topper Purchases 4,005 SharesNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) Director James N. Topper bought 4,005 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The shares were purchased at an average cost of $21.02 per share, for a total transaction of $84,185.10. Following the acquisition, the director now owns 3,012,434 shares of the company's stock, valued at $63,321,362.68. This represents a 0.13 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website.March 7, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Sees Large Volume Increase - Time to Buy?NewAmsterdam Pharma (NASDAQ:NAMS) Sees Strong Trading Volume - Should You Buy?March 7, 2025 | marketbeat.comInsider Buying: NewAmsterdam Pharma (NASDAQ:NAMS) Director Buys 4,005 Shares of StockMarch 7, 2025 | insidertrades.comDirector’s Bold Move: Major Stock Purchase in NewAmsterdam Pharma!March 6, 2025 | tipranks.comNewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells $3,055,500.00 in StockNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) CAO Louise Frederika Kooij sold 150,000 shares of the stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total value of $3,055,500.00. Following the transaction, the chief accounting officer now owns 15,000 shares of the company's stock, valued at approximately $305,550. The trade was a 90.91 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.March 6, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Up 3.9% - Should You Buy?NewAmsterdam Pharma (NASDAQ:NAMS) Trading 3.9% Higher - What's Next?March 5, 2025 | marketbeat.comNewAmsterdam Pharma price target raised to $41 from $35 at GuggenheimMarch 3, 2025 | markets.businessinsider.comLeerink Partnrs Has Negative Outlook of NAMS FY2028 EarningsNewAmsterdam Pharma (NASDAQ:NAMS - Free Report) - Equities researchers at Leerink Partnrs decreased their FY2028 EPS estimates for shares of NewAmsterdam Pharma in a research report issued to clients and investors on Thursday, February 27th. Leerink Partnrs analyst R. Ruiz now anticipates that thMarch 3, 2025 | marketbeat.comWilliam Blair Has Negative Forecast for NAMS Q1 EarningsNewAmsterdam Pharma (NASDAQ:NAMS - Free Report) - Investment analysts at William Blair reduced their Q1 2025 earnings estimates for shares of NewAmsterdam Pharma in a note issued to investors on Wednesday, February 26th. William Blair analyst M. Phipps now forecasts that the company will earn ($0March 3, 2025 | marketbeat.comNewAmsterdam Pharma files for $500M mixed securities shelfMarch 1, 2025 | seekingalpha.comNewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of ObicetrapibMarch 1, 2025 | seekingalpha.comNewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of ObicetrapibMarch 1, 2025 | seekingalpha.comNewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Yearly Results: Here's What Analysts Are Forecasting For This YearFebruary 28, 2025 | finance.yahoo.com Remove Ads Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter. Email Address NAMS Media Mentions By Week NAMS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NAMS News Sentiment▼0.700.83▲Average Medical News Sentiment NAMS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NAMS Articles This Week▼125▲NAMS Articles Average Week Remove Ads Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Roivant Sciences News Lantheus News TG Therapeutics News Revolution Medicines News BridgeBio Pharma News Legend Biotech News Blueprint Medicines News Sarepta Therapeutics News Krystal Biotech News Axsome Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NAMS) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
